Cadrenal Therapeutics Inc (CVKD) - News Archive

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, has announced a significant advancement in its clinical pipeline....

PONTE VEDRA, Fla. Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) has recently delivered a comprehensive year-end update for 2024, illuminating its ambitious vision for the investigational drug tecarfarin. As a pioneering ef...

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications PONTE VEDRA, Fla. Cadrenal Therapeutics, Inc. (Nasdaq:...

Cadrenal Therapeutics Charts a Promising Course for Tecarfarin Development in 2024: A New Dawn for Anticoagulant Therapy in Cardiovascular Care Cadrenal Therapeutics, based in Ponce de Leon, Florida, recently provided a...